Eli Lilly’s next-generation obesity treatment shows promise for patients with high BMI or obesity-related complications. The company’s diverse portfolio sets it up for growth through 2026, making it a smart long-term investment. Results from a phase 3 clinical trial for retatrutide demonstrate significant weight reduction and pain relief, surpassing leading anti-obesity drugs. The drug could be a potent competitor in the weight-loss market, with potential revenue of $5 billion by 2030.

Lilly expects retatrutide to provide rapid weight loss for patients with high BMI or obesity-related issues, targeting different segments in the weight-loss market. The company also plans additional phase 3 trials for obesity and type 2 diabetes. With a potential market value of $150 billion by 2035, retatrutide could capture a significant share. Lilly dominates the U.S. market for incretin-mimicking drugs, with strong revenue potential internationally.

Eli Lilly is expanding its obesity treatment options with orforglipron, aiming for FDA approval by March 2026. The drug is expected to reduce the injection burden for patients using GLP-1 drugs, with potential annual revenue of $8.3 billion by 2030. The company also sees growth opportunities in the Alzheimer’s and oncology markets, with revenue estimates rising for 2025.

Management has raised revenue and earnings guidance for 2025, reflecting positive catalysts. Although Eli Lilly’s stock valuation may seem high, its leadership in the obesity treatment market and strong research pipeline justify the price. Long-term investors could benefit from investing before 2026, ignoring short-term fluctuations. Consider the potential of Eli Lilly alongside other top stock picks for significant returns.

Read more at Yahoo Finance: Is Eli Lilly a Buy Before 2026?